Exicure, Inc.(XCUR)

Biotechnology · Redwood City, CA

$1.08+0.01 (+0.93%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Exicure (XCUR) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T22:14:09.024Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:14:09.024Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 6,883,852
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 1,717,000
TTM operating EBITDA · period ending 2026-06-30: -6,930,000

FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

XCUR EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

XCUR Competitors' EV/EBITDA Ratio

XCUR

Exicure, Inc.

Current

Market Cap

$6.88M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLT

Bolt Biotherapeutics, Inc.

vs XCUR

Market Cap

$6.74M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA

KALA BIO, Inc.

vs XCUR

Market Cap

$7.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs XCUR

Market Cap

$7.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SKYE

Skye Bioscience, Inc.

vs XCUR

Market Cap

$7.12M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LGVN

Longeveron Inc.

vs XCUR

Market Cap

$7.15M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMRA

Biomerica, Inc.

vs XCUR

Market Cap

$6.61M

EV/EBITDA Ratio

N/A

TTM Avg

96.60x

3Y Avg

88.71x

5Y Avg

504.98x

ENSC

Ensysce Biosciences, Inc.

vs XCUR

Market Cap

$6.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACON

Aclarion, Inc.

vs XCUR

Market Cap

$6.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENVB

Enveric Biosciences, Inc.

vs XCUR

Market Cap

$6.58M

EV/EBITDA Ratio

N/A

TTM Avg

34.26x

3Y Avg

34.26x

5Y Avg

668.76x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Exicure, Inc. (XCUR)	$6.88M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.74M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.04M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.07M	N/A	N/A	N/A	N/A
Skye Bioscience, Inc. (SKYE)vs ›	$7.12M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.15M	N/A	N/A	N/A	N/A
Biomerica, Inc. (BMRA)vs ›	$6.61M	N/A	96.60x	88.71x	504.98x
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.60M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.60M	N/A	N/A	N/A	N/A
Enveric Biosciences, Inc. (ENVB)vs ›	$6.58M	N/A	34.26x	34.26x	668.76x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics